

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AID Life Science Holdings Limited**  
**( 滙友生命科學控股有限公司 )\***  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 8088)**

**PROFIT WARNING**

This announcement is made pursuant to Rule 17.10 of the Rule Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of AID Life Science Holdings Limited (the “**Company**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited financial information of the Company and its subsidiaries (collectively the “**Group**”), the Group is expected to record a 30% to 40% decrease in loss for the three months ended 31 March 2020 (the “**Period**”) as compared to that for the three months ended 31 March 2019. The decrease in loss was mainly attributable to decrease in research and development costs and amortisation of intangible assets after the disposal of GeneSort.

As the Group is still in the course of finalizing its consolidated financial results for the Period, the information contained in this announcement is only based on the unaudited draft consolidated financial statements of the Group for the Period, which have not been audited by the auditors of the Company nor reviewed by the audit committee of the Board as at the date of this announcement and is subject to possible adjustments upon further review. Shareholders and potential investors are advised to read carefully the first quarterly results announcement of the Group for the Period which is expected to be published by mid-May 2020.

\* For identification purpose only

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board  
**AID Life Science Holdings Limited**  
**Wu King Shiu, Kelvin**  
*Chairman*

Hong Kong, 4 May 2020

*As at the date of this announcement, the Directors are:*

*Chairman and Non-Executive Director:* Wu King Shiu, Kelvin

*Executive Directors:* Chan Suet Ngan, Hu Kenneth and  
Qian Alexandra Gaochuan

*Independent Non-Executive Directors:* Yuen Kwok On, Matsumoto Hitoshi and  
Yau Chung Hang

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this announcement misleading.*

*This announcement will remain on the GEM website at [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the website of the Company at [www.8088inc.com](http://www.8088inc.com).*